Colinz Labs

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE923C01011
  • NSEID:
  • BSEID: 531210
INR
63.79
-5.21 (-7.55%)
BSENSE

Nov 20

BSE+NSE Vol: 533

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
{
  "main_header": {
    "sid": 621096,
    "name": "Colinz Labs",
    "stock_name": "Colinz Labs",
    "full_name": "Colinz Laboratories Ltd",
    "name_url": "stocks-analysis/colinz-labs",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "63.79",
    "chg": -5.21,
    "chgp": "-7.55%",
    "dir": -1,
    "prev_price": "69.00",
    "mcapval": "17.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 531210,
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE923C01011",
    "curr_date": "Nov 20",
    "curr_time": "",
    "bse_nse_vol": "533 ",
    "exc_status": "Active",
    "traded_date": "Nov 20, 2026",
    "traded_date_str": "2026 11 20",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://researchintel.adityabirlamoney.com/ABML-Landingstocks-analysis/colinz-labs-621096-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Colinz Laboratories Ltd: Valuation Shift Signals Renewed Price Attractiveness",
        "link": "https://researchintel.adityabirlamoney.com/news/stocks-in-action/colinz-laboratories-ltd-valuation-shift-signals-renewed-price-attractiveness-4251250",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/11/ColinzLaborator_valuationdot_4251250.png",
        "date": "2026-11-05 08:01:45",
        "description": "Colinz Laboratories Ltd has witnessed a notable shift in its valuation parameters, moving from an expensive to a fair valuation grade, reflecting evolving investor perceptions amid a mixed performance backdrop. This recalibration comes as the company’s price-to-earnings (P/E) ratio moderates to 35.05, aligning more closely with sector peers, while price-to-book value (P/BV) stands at 1.73, signalling a more balanced price attractiveness compared to historical levels."
      },
      {
        "title": "Colinz Laboratories Ltd Valuation Shifts Signal Growing Price Pressure",
        "link": "https://researchintel.adityabirlamoney.com/news/stocks-in-action/colinz-laboratories-ltd-valuation-shifts-signal-growing-price-pressure-4243897",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/10/ColinzLaborator_valuationdot_4243897.png",
        "date": "2026-10-30 08:01:44",
        "description": "Colinz Laboratories Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its valuation metrics shift notably towards an expensive zone, reflecting a significant change in market perception. Despite this, the company’s stock has delivered robust returns over multiple time frames, outperforming the Sensex by a wide margin."
      },
      {
        "title": "Colinz Laboratories Ltd Valuation Shifts Signal Improved Price Attractiveness",
        "link": "https://researchintel.adityabirlamoney.com/news/stocks-in-action/colinz-laboratories-ltd-valuation-shifts-signal-improved-price-attractiveness-4232707",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/10/ColinzLaborator_valuationdot_4232707.png",
        "date": "2026-10-22 08:01:00",
        "description": "Colinz Laboratories Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has witnessed a notable shift in its valuation parameters, moving from an expensive to a fair valuation grade. This change, coupled with its robust returns over multiple time horizons, invites a closer examination of its price attractiveness relative to historical levels and peer benchmarks."
      },
      {
        "title": "Colinz Laboratories Ltd Valuation Shifts Signal Renewed Price Attractiveness",
        "link": "https://researchintel.adityabirlamoney.com/news/stocks-in-action/colinz-laboratories-ltd-valuation-shifts-signal-renewed-price-attractiveness-4224683",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/10/ColinzLaborator_valuationdot_4224683.png",
        "date": "2026-10-14 08:00:37",
        "description": "Colinz Laboratories Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its valuation parameters, moving from an expensive to a fair valuation grade. This transition reflects evolving market perceptions amid robust stock performance and changing fundamentals, prompting a downgrade in its Mojo Grade from Hold to Sell as of 19 June 2026."
      },
      {
        "title": "Colinz Laboratories Ltd Valuation Shifts Signal Renewed Price Attractiveness",
        "link": "https://researchintel.adityabirlamoney.com/news/stocks-in-action/colinz-laboratories-ltd-valuation-shifts-signal-renewed-price-attractiveness-4180197",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/9/ColinzLaborator_valuationdot_4180197.png",
        "date": "2026-09-03 08:00:55",
        "description": "Colinz Laboratories Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen a notable shift in its valuation parameters, moving from an expensive to a fair valuation grade. This change reflects evolving market sentiment amid fluctuating price-to-earnings (P/E) and price-to-book value (P/BV) ratios, alongside a broader assessment of its financial health and peer comparisons."
      }
    ],
    "total": 26,
    "sid": "621096",
    "stock_news_url": "https://researchintel.adityabirlamoney.com/news/colinz-laboratories-621096"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
      "datetime": "31-Oct-2026",
      "details": "Dear sir",
      "source": "BSE"
    },
    {
      "caption": " Outcome Of The Board Meeting Under Regulation 30 And 33 Of SEBI (Listing Obligation And Disclosure Requirements) Regulations 2015.",
      "datetime": "29-Oct-2026",
      "details": "The Attached Results for Quarter ended on 30-9-2026 was approved in Bopard Meeting held on 29-10-2026 as required under Regulation 30 and 33 and our Auditors have issued Limited Review Report on the same.",
      "source": "BSE"
    },
    {
      "caption": "Board Meeting Outcome for Outcome Of The Board Meeting Under Regulation 30 And 33 Of SEBI (Listing Obligation And Disclosure Requirements) Regulations 2015.",
      "datetime": "29-Oct-2026",
      "details": "We would like to inform you that the Board of Directors of the Company at their meeting held today i.e. 29th October 2026 has inter alia considered and approved Unaudited Financial Results (as per IND-AS) for the quarter and half year ended on 30th September 2026.",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}
stock newsNews and Views
stock-recommendationAnnouncement

Announcement under Regulation 30 (LODR)-Newspaper Publication

31-Oct-2026 | Source : BSE

Dear sir

Outcome Of The Board Meeting Under Regulation 30 And 33 Of SEBI (Listing Obligation And Disclosure Requirements) Regulations 2015.

29-Oct-2026 | Source : BSE

The Attached Results for Quarter ended on 30-9-2026 was approved in Bopard Meeting held on 29-10-2026 as required under Regulation 30 and 33 and our Auditors have issued Limited Review Report on the same.

Board Meeting Outcome for Outcome Of The Board Meeting Under Regulation 30 And 33 Of SEBI (Listing Obligation And Disclosure Requirements) Regulations 2015.

29-Oct-2026 | Source : BSE

We would like to inform you that the Board of Directors of the Company at their meeting held today i.e. 29th October 2026 has inter alia considered and approved Unaudited Financial Results (as per IND-AS) for the quarter and half year ended on 30th September 2026.

stock-recommendationCorporate Actions
Corporate Actions
info
stock-summary
BOARD MEETING

No Upcoming Board Meetings

stock-summary
DIVIDEND

No Dividend history available

stock-summary
SPLITS

No Splits history available

stock-summary
BONUS

No Bonus history available

stock-summary
RIGHTS

No Rights history available